Biotech SF

San Francisco Bay Area biotech stories.

Friday, January 14, 2011

Melanoma drug, companion diagnostic marry Plexxikon, Roche Molecular Diagnostics

Posted by Unknown at 11:55 AM
Email ThisBlogThis!Share to XShare to FacebookShare to Pinterest
Labels: Plexxikon, Roche Molecular Diagnostics

No comments:

Post a Comment

Newer Post Older Post Home
Subscribe to: Post Comments (Atom)

TOP STORIES

  • Patients' tales, biotech legends add weight to BayBio awards
    Genentech co-founder Herb Boyer. When two or more biotechs are gathered, you hear the usual phrases, including the old standby, “We'...
  • Former Genentech exec Marc Tessier-Lavigne elected to Pfizer board
    Former Genentech Inc. chief scientific officer Marc Tessier-Lavigne was elected to Pfizer Inc.’s board of directors. Tessier-Lavigne, who j...
  • Stanford team wins $20K for algorithm aimed at Lou Gehrig's disease drug trials
    Lester Mackey. A team from Stanford University won $20,000 for its work with algorithms that could reduce the number of Lou Gehrig’s Dis...
  • Nation's HIV research general Tony Fauci: Cure in 'discovery phase'
    Dr. Tony Fauci. As director of the National Institute of Allergy and Infectious Diseases for the past 28 years, Tony Fauci has seen the ...
  • One-on-One with Roche Molecular Diagnostics' Paul Brown
    In the personalized medicine revolution, Roche Molecular Diagnostics is positioned to be the major arms supplier. The Pleasanton-based unit...

Some of my favorite stories.

• "The fight of his life" (2007)
Last year Mike Homer helped raise the money for 2,000 medical research computers. Now researchers are using that equipment in an attempt to save his life.

• "For reporter, CJD is more than a story" (2007)
Seven years ago -- nearly to the day -- my mother died of Creutzfeld-Jakob Disease.

• "A son's YouTube plea for Avastin" (2010)
Josh Turnage is your typical teenager, trying to discover what he wants to do in college and with his life. But a 7-minute, 41-second YouTube video he produced about his mother's fight with breast cancer may thrust him into a debate between drug makers and the agency that regulates them.

• "New device could knock out old dialysis technology" (2011)
Shuvo Roy has all the makings for the world's first implantable artificial kidney, thanks to nanotechnology and a web of nationwide collaborations.
All he needs now is $20 million.

Subscribe To

Posts
Atom
Posts
Comments
Atom
Comments

Blog Archive

  • ►  2012 (486)
    • ►  November (18)
    • ►  October (25)
    • ►  September (56)
    • ►  August (56)
    • ►  July (64)
    • ►  June (26)
    • ►  May (40)
    • ►  April (39)
    • ►  March (31)
    • ►  February (74)
    • ►  January (57)
  • ▼  2011 (772)
    • ►  December (54)
    • ►  November (40)
    • ►  October (65)
    • ►  September (74)
    • ►  August (48)
    • ►  July (44)
    • ►  June (60)
    • ►  May (70)
    • ►  April (80)
    • ►  March (81)
    • ►  February (77)
    • ▼  January (79)
      • Onyx multiple myeloma drug wins FDA fast-track status
      • UCSF nabs $20M gift from Ray and Dagmar Dolby for ...
      • Douglas Rosenberg invests $3.5M toward Alzheimer's...
      • BiPar breast cancer drug fails late-stage trial
      • Genentech's Rituxan wins FDA approval for advanced...
      • Fluidigm prices IPO at $13.50 to $15 per share
      • Success with Genentech cancer drug Tarceva could e...
      • Bionovo to raise $30M for R&D
      • UCSF to hire more San Francisco residents for hosp...
      • Portola Pharmaceuticals targets antidote to blood ...
      • Plexxikon starts Phase I trial of rheumatoid arthr...
      • $26.3M Eye Institute at Stanford named for VC gian...
      • FDA warns Genentech about Boniva ad with Sally Field
      • The plane truth: Elan execs take flight in face of...
      • Report: Elan cuts 130 jobs, mainly in South SF, as...
      • FDA wants more info on Gilead-Tibotec HIV drug combo
      • Codexis signs deal with Japan's Dainippon Sumitomo...
      • Abaxis inks $30 million supply deal with Becton Di...
      • Nektar nets $220M from stock sale
      • Portola Pharma names 1st head of R&D
      • AcelRx Pharmaceuticals prices $81 million IPO
      • UCSF harvesting Big Pharma deals
      • Genomic Health hiring 50-100, expanding to 3rd bui...
      • Genomic Health pedals way to growth
      • California stem cell agency CIRM taps Amgen exec f...
      • Transcept awakens bid for sleeping pill approval
      • Venture investing way up in '10, modest increase i...
      • Corcept Therapeutics to sell $39M in stock
      • View from personalized medicine confab
      • Gordon & Rees starts life sciences practice
      • Nektar Therapeutics to sell 19M shares
      • Plexxikon, Roche melanoma drug improves survival
      • Protagonist Therapeutics, Ironwood Pharma sign pep...
      • Amgen to sell Fremont campus to Boehringer Ingelheim
      • Nektar Therapeutics plans stock sale
      • Alexza shares plummet after FDA setback
      • Genentech fires back at FDA over Avastin breast ca...
      • Calif. AG leads battle against Bayer, 'reverse pay...
      • UCSF opening $15.5 million high-tech learning center
      • We are the world: Bay Area remains center of biotech
      • Melanoma drug, companion diagnostic marry Plexxiko...
      • Index Ventures opening Bay Area office
      • Medtronic completes $800M acquisition of Ardian
      • In autism's storm: 2 champions stand firm in light...
      • Biotechs fight proposed building code in South S.F.
      • FibroGen launches mid-stage IPF drug trial
      • SRI International lands $17.4M in NIH deals
      • Codexis inks enzyme supply deal with DSM Pharm
      • UCSF, Sanofi-Aventis ink research, intern deal
      • Dynavax fills late-stage hepatitis vaccine trial
      • NextWave Pharmaceuticals raises $45M
      • Fast facts from J.P Morgan's 1st day
      • Bayer, UCSF ink master deal, but few details
      • Sangamo gives layoffs the zinc finger
      • OncoMed starts early test of solid tumor cancer drug
      • What's up at the J.P. Morgan conference — so far
      • Exelixis cancer drug wins 'orphan' tag
      • InterMune to start new IPF drug trial
      • JP Morgan Healthcare Conference: And they're off …
      • IPierian wants closer ties to 'father' of induced ...
      • 23andMe snags another $9M in funding
      • Executive Profile: iPierian CEO Michael Venuti
      • StemCells lines up $10M stock financing
      • UCSF, University of Michigan, Cleveland Clinic art...
      • Avastin, Esbriet drug approvals: Go figure
      • Pfizer, Sutro cut peptide drug research deal
      • J.P. Morgan Healthcare Conference tops 2010 numbers
      • InterMune IPF drug strategy pays off
      • Affymax names new CEO, director
      • Genentech, Plexxikon ink sales deal
      • Denmark's Symphogen raises $130 million
      • FDA OKs expanded use of Genentech rheumatoid arthr...
      • Med device company PneumRx raises $33M
      • Boston Scientific buys remainder of Sadra Medical ...
      • Genentech licenses NY biotech's potential antibact...
      • Xoma gets flexibility in Servier deal, must deliver
      • Xoma snags up to $505M, including $35M upfront, fo...
      • New biotech conference crowds J.P. Morgan Week sch...
      • Biotech in '11: Life science firms dive into great...
  • ►  2010 (59)
    • ►  December (42)
    • ►  November (17)

Search This Blog

TWITTER UPDATES

Dates to Watch

Sept. 5 - PDUFA date for Salix Pharmaceuticals' crofelemer (developed by San Francisco's Napo Pharmaceuticals) for diarrhea in HIV/AIDS patients on antiretroviral therapy.
Oct. 19 - PDUFA date for Impax Pharmaceutical's IPX-066 in Parkinson's
Oct. 23 - PDUFA date for Hyperion Therapeutics' Ravicti in urea cycle disorders.

Calendar

  • "Ushering in the New Medical Device Excise Tax: Will You Be Ready?" 8 a.m. Wednesday, Sept. 5, Abbott Vascular, 3200 Lakeside Drive, Santa Clara. Cost: $20 BayBio members, $40 non-members (through Sept. 3) and $40 members and $75 non-members (after Sept. 3)
Unknown
View my complete profile

My contact information

Ron Leuty
San Francisco Business Times
275 Battery St.,
Suite 940
San Francisco,
CA 94111
415-288-4939 - direct
415-722-2678 - cell
rleuty@
bizjournals.com
http://www.bizjournals.com/sanfrancisco

Follow me on Twitter — rleuty_biotech
— or Facebook or LinkedIn.

For biotech stories from all of ACBJ's 40 business journals — from Boston to Seattle — go to Biotech Day.

Followers

Total Pageviews
Simple theme. Powered by Blogger.